Kinase | Inhibitors | Development Stage | Disease Indication | Comments |
---|---|---|---|---|
IKK (NF-κB) | IMD-0354 | Phase 2? | COPD | Discontinued |
Bay 65-1942 | Preclinical | COPD | Oral | |
p38 MAPK | Dilmapimod | Phase 2 | COPD | Oral |
Losmapimod | Phase 2 | COPD | Oral | |
PH-797804 | Phase 2 | COPD | Oral | |
PF-03715455 | Phase 2 | Asthma, COPD | Inhaled | |
AZD7624 | Phase 2 | COPD | Inhaled | |
RV-568 | Phase 2 | COPD | Inhaled | |
JNK | SP600125 | Preclinical | Asthma, COPD? | Oral |
MEK1/ERK | Trametinib | Phase 3 | Cancer | Oral |
ASK-1 | GS-4997 | Phase 2 | Diabetes | Oral |
PI3K | Idelisib | Approved | B cell malignancy | Oral PI3Kδ-selective |
TG100-115 | Preclinical | Asthma, COPD | InhaledPI3Kγ/δ-selective | |
GSK2269557 | Phase 2 | COPD | Inhaled PI3Kδ-selective | |
RV-1729 | Phase 2 | Asthma, COPD | Inhaled PI3Kγ/δ-selective | |
JAK | LAS194046 | Preclinical | Asthma, COPD | Inhaled |
R256 | Preclinical | Asthma, COPD | Inhaled | |
VR560 | Preclinical | Asthma, COPD | Inhaled | |
SYK | Fostamatinib | Phase 3 | Arthritis, lymphoma | Oral |
R112 | Phase 2 | Rhinitis | Nasal, discontinued | |
R343 | Phase 2 | Asthma | Inhaled, discontinued | |
LAS189386 | Preclinical | Asthma | Inhaled | |
RTK | BIBW 2948 | Phase 2 | COPD | Inhaled EGFR |
Masitinib | Phase 2 | Severe asthma | Oral, PDGFR, c-Kit | |
ROCK | Fasudil | Approved | Cerebral vasospasm | Oral |
ASK, apoptosis signal-regulatory kinase; EGFR, epidermal growth factor receptor; ERK, extracellular regulating kinase; IKK, inhibitor of kB kinase; JAK, Janus-activated kinase; JNK, Jun NH2-terminal kinase; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-kappa B; PDGFR, platelet-derived growth factor receptor; PI3K, phosphoinositide-3-kinase; ROCK, Rho-associated protein kinase; RTK, receptor tyrosine kinase; Syk, spleen tyrosine kinase.